• About us
• Contact

Advertisement

Organisation › Details

Forschungsinstitut für molekulare Pathologie GmbH (IMP, Research Institute for Molecular Pathology)

The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 40 countries, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. *

 

	Start	1997-02-01 existent
	Group	Boehringer Ingelheim (Group)
	Industry	pathology
	Industry 2	molecular biology
	Region	Wien (Vienna)
	Country	Austria
	Street	7 Dr. Bohr-Gasse
	City	1030 Wien
	Tel	+43-1-79730
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Quantro Therapeutics GmbH. (7/21/20). "Press Release: Quantro Therapeutics Launched with Breakthrough Oncology Drug Discovery Platform". Vienna.
		Record changed: 2025-03-16

Advertisement

More documents for Boehringer Ingelheim (Group)

• [1] Tessellate Bio B.V.. (4/23/25). "Press Release: Boehringer Ingelheim and Tessellate Bio Partner to Develop First-in-class Precision Treatments for People with Hard-to-treat Cancers". Ingelheim & Amsterdam....
• [2] Boehringer Ingelheim. (4/3/25). "Press Release: Boehringer Ingelheim Strengthens Antibody-Drug Conjugate Portfolio with New NBE Therapeutics R&D Center in Basel". Basel....
• [3] Boehringer Ingelheim. (4/2/25). "Press Release: Boehringer Ingelheim Reaches more Patients in 2024 and Prepares New Medicine Launches". Ingelheim....
• [4] Salipro Biotech AB. (3/13/25). "Press Release: Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs". Stockholm....
• [5] Veeva Systems Inc.. (3/11/25). "Press Release: Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’". Ingelheim & Pleasonton, CA....
• [6] Boehringer Ingelheim. (3/4/25). "Press Release: Boehringer Ingelheim Enhances Biopharmaceutical Contract Manufacturing Services in China". Ingelheim....
• [7] Boehringer Ingelheim. (2/20/25). "Press Release: Boehringer Ingelheim and Partners Start Clinical Development of a First-in-Class, Inhaled Gene Therapy for People with Cystic Fibrosis". Ingelheim....
• [8] Boehringer Ingelheim. (1/16/25). "Press Release: Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia". Ingelheim....
• [9] Boehringer Ingelheim. (1/9/25). "Press Release: Boehringer Ingelheim Broadens Oncology Portfolio with License for Synaffix’s ADC Technology". Amsterdam, Basel & Ingelheim....
• [10] Boehringer Ingelheim. (10/9/24). "Press Release: Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment". Ingelheim & South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.